Daily Market Reports | 10:40 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
AAR ARX CAR CQE (2) CVN ERD GLL IRE JBH MM8 NUZ PLT PXA RWC TPW WGX
AAR ASTRAL RESOURCES NL
Gold & Silver - Overnight Price: $0.17
Canaccord Genuity rates ((AAR)) as Buy (1) -
Canaccord Genuity notes Astral Resources' latest assay results highlight more opportunity to increase resources at the three deposits at the Feysville project attached to the Mandilla gold project.
In June, the company released the pre-feasibility study (PFS) for the Mandilla gold project which outlined annual production of 76koz/annum at cost of $2,085/oz over an initial 19-year operation.
The broker reckons the latest results will support the PFS.
Buy. Target price 64c (was 49c in April, before it was raised to 64c in early July).
This report was published on August 11, 2025.
Target price is $0.64 Current Price is $0.17 Difference: $0.47
If AAR meets the Canaccord Genuity target it will return approximately 276% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.00.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ARX AROA BIOSURGERY LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.64
Wilsons rates ((ARX)) as Overweight (1) -
Wilsons maintained its Overweight rating on Aroa Biosurgery following positive June quarter updates from its peers and competitors.
The broker notes US commercial partner TELA Bio is showing strong momentum, especially with PRS product expansion planned over several years.
The company itself is building a Myriad product family for high-value surgical indications where infection-resistant, implantable devices are most compelling to surgeons.
On the regulatory side, the broker believes the US Centers for Medicare & Medicaid Services' proposed reforms to curb the skin substitutes market could level the playing field and open opportunities for Symphony.
Minor changes to forecasts. Target price 82c.
This report was published on August 12, 2025.
Target price is $0.82 Current Price is $0.64 Difference: $0.18
If ARX meets the Wilsons target it will return approximately 28% (excluding dividends, fees and charges).
The company's fiscal year ends in March.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.18 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 349.73.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.27 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 233.58.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CAR CAR GROUP LIMITED
Automobiles & Components - Overnight Price: $40.04
Jarden rates ((CAR)) as Neutral (3) -
After detailed analysis of CAR Group's FY25 result, Jarden notes operating momentum remains strong with FY26 net profit guidance of 9-13% growth comparing with consensus of 12% before the result.
For FY26, the broker is forecasting 13.2% revenue growth vs guidance of 12-14%, and group EBITDA of 12.5% vs 10-13% guidance. North American organic revenue growth was the focus, and the broker estimates 11.6% revenue and 12.3% EBITDA growth.
The broker also forecasts margin expansion in Australia and Latin America. Overall, FY26 EPS forecast trimmed by -1.9% and FY27 by -3.6%, mainly due to below-the-line items.
Neutral. Target unchanged at $34.50.
This report was published on August 12, 2025.
Target price is $34.50 Current Price is $40.04 Difference: minus $5.54 (current price is over target).
If CAR meets the Jarden target it will return approximately minus 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $42.14, suggesting upside of 5.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 90.00 cents and EPS of 115.70 cents.
At the last closing share price the estimated dividend yield is 2.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 34.61.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 110.9, implying annual growth of 52.0%.
Current consensus DPS estimate is 88.8, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 36.1.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 99.00 cents and EPS of 123.40 cents.
At the last closing share price the estimated dividend yield is 2.47%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 32.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 126.6, implying annual growth of 14.2%.
Current consensus DPS estimate is 101.3, implying a prospective dividend yield of 2.5%.
Current consensus EPS estimate suggests the PER is 31.6.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE